AstraZeneca’s Combination Therapy Shows Significant Efficacy in Phase III Trial Cambridge, UK- On Monday, AstraZeneca’s combination of Truqap (capivasertib) with Faslodex (fulvestrant) received a recommendation for approval from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This recommendation pertains to the treatment of adult patients with estrogen receptor … Continue reading Truqap Plus Faslodex Recommended for EU Approval in Advanced Breast Cancer Treatment